Perinatal and Wharton&apos;s jelly-derived mesenchymal stem cells in cartilage regenerative medicine and tissue engineering strategies by LO IACONO, M. et al.
72 The Open Tissue Engineering and Regenerative Medicine Journal, 2011, 4, 72-81  
 
 1875-0435/11 2011 Bentham Open 
Open Access 
Perinatal and Wharton’s Jelly-Derived Mesenchymal Stem Cells in 
Cartilage Regenerative Medicine and Tissue Engineering Strategies 
Melania Lo Iacono1,§, Rita Anzalone*,1,§, Simona Corrao1, Mario Giuffrè2, Antonino Di Stefano3, 
Pantaleo Giannuzzi4, Francesco Cappello1, Felicia Farina1 and Giampiero La Rocca1 
1Sezione di Anatomia Umana, Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Università degli 
Studi di Palermo, Palermo, Italy 
2Unità Complessa di Pediatria e Terapia Intensiva Neonatale, Dipartimento Universitario Materno Infantile, Università 
degli Studi di Palermo, Palermo, Italy 
3Laboratorio di Citoimmunopatologia Apparato Cardio Respiratorio, Fondazione S. Maugeri, IRCCS, Istituto 
Scientifico di Veruno (NO), Italy  
4Divisione di Cardiologia, Fondazione S. Maugeri, IRCCS, Istituto Scientifico di Veruno (NO), Italy  
Abstract: Stem cells can be found in embryonic and extraembryonic tissues as well as in adult organs. In particular, 
research in the last few years has delineated the key features of perinatal stem cells derived from fetus-associated tissues. 
These cells show multiple differentiation potential, can be easily expanded ex vivo, and raise no ethical concerns as 
regards their use. Several reports indicate that cells isolated from Wharton's jelly (WJ), the main component of umbilical 
cord extracellular matrix, are multipotent stem cells that express markers shared by other mesenchymal stem cells (MSC) 
and give rise to different mature cell types belonging to all three germ layers. Moreover, WJ-MSC display promising 
hypoimmunogenic and immunomodulatory properties, since they express molecules able to modulate NK cells and 
expand regulatory T-cell populations.  
In this review, we focus on the use of perinatal stem cells for regenerative medicine aimed at cartilage repair and 
regeneration. Cartilage is a specialized connective tissue which has poor regeneration and self-repair capacity in vivo. 
Traumatic injury or autoimmune processes are among the main causes of cartilage damage and degeneration, for which 
new hope comes from tissue engineering using stem cells which have undergone chondrocyte-like differentiation. We 
analyze the in vitro and in vivo data on the use of perinatal stem cells, in particular WJ-MSC, for cartilage regenerative 
medicine. The high variability of cell sources, the use of different types of scaffolds and matrixes, and the administration 
of several combinations of growth factors clearly point out the need for further research to optimize this cellular therapy 
approach and translate the results obtained from bench to clinic. 
Keywords: Articular cartilage, Chondrocytes, Differentiation markers, Extracellular matrix, Mesenchymal stem cells, 
scaffolds, Tissue engineering, Umbilical cord, Wharton’s jelly. 
1. INTRODUCTION 
 The umbilical cord (UC) is an extraembryonic formation 
that constitutes the essential link between placenta and fetus 
during pregnancy. It is covered by the umbilical epithelium, 
called also amniotic epithelium, layered with cubic epithelial 
cells [1]. The inner structure of the umbilical cord is 
composed of umbilical vessels, two arteries and one vein, 
embedded in mucous connective tissue known as Wharton’s 
jelly (WJ). It contains an abundant extracellular matrix 
composed of sparse collagen fibers and an amorphous 
substance. The main role of Wharton’s jelly is to prevent 
torsion, compression and bending of the vessels, maintaining 
the two-way flow of blood between maternal and fetal 
circulations. WJ is rich in proteoglycans such as hyaluronic  
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acid and two cell types: myofibroblasts and fibroblast-like 
cells [2]. Weiss and co-workers have shown that Wharton’s 
jelly cells (WJC) express osteopontin gene [3], a major 
component of the hematopoietic stem cell niche and a 
regulator of hematopoietic progenitor cells [4]. Hyaluronic 
acid is another main component of the hematopoietic stem 
cell niche and WJC are a likely source of hyaluronic acid [5]. 
The expression of such molecules may in part explain the ex 
vivo hematopoietic expansion features of WJC [6]. Further-
more, WJC favor the in vivo engraftment of hematopoietic 
stem cells [7, 8]. In addition, WJC also promote growth of 
embryonic stem cells and embryonic-like stem cells [9]. 
2. MAIN FEATURES OF WHARTON’ S JELLY 
MESENCHYMAL STEM CELLS 
 Of the two cell types described in Wharton’s jelly [2], 
myofibroblasts have ultrastructural characteristics of both 
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fibroblasts and smooth muscle cells. They could play a role 
in fibrogenesis and contraction. [10]. Fibroblast-like cells, 
which constitute the mesenchymal stem cells (MSC) popula-
tion, are multipotent stem cells, grow robustly in vitro, can 
be deep-frozen for long-term storage, and maintain a 
morphology similar to fibroblasts during their culture. 
 WJ-MSC show a phenotype closely resembling that of 
bone marrow mesenchymal stem cells (BM-MSC): in fact 
they express CD10, CD13, CD29, CD44, CD49e, CD73, 
CD90, CD105, CD166 and HLA class I. Like BM-MSC, 
they lack expression of hematopoietic markers such as CD34 
and CD45, endothelial markers (CD31, vWF) and HLA-DR 
[3, 6, 11]. Moreover, and in contrast to BM-MSC, some pre-
parations of WJ-MSC express CD117 [12], CD68 [13], and 
CD14 [14]. More recently, transcriptomic analyses allowed 
to deep-define the breadth of differences between WJ-MSC 
and other MSC populations [15]. 
 Recent research by our group and others has demons-
trated that WJ-MSC express mesodermal markers such as 
vimentin and α-smooth muscle actin; endodermal markers 
like Gata-4, Gata-5, Gata-6, HNF4-α; and neuro-ectodermal 
markers like nestin, neuron specific enolase (NSE) and glial 
fibrillary acid protein (GFAP). These data support the notion 
that these cells can differentiate towards different mature cell 
types derived from all three germ layers [12]. As for other 
MSC populations, according to the Position Statement of the 
International Society for Cellular Therapy, WJ-MSC are 
defined as multipotent stem cells since they can differentiate 
into at least three different cellular lineages: osteoblasts, 
adipocytes and chondrocytes [16]. 
 WJ-MSC cultured in a medium opportunely supple-
mented with factors inducing osteogenic differentiation can 
express osteonectin, osteopontin, periostin and runx2 genes 
and proteins. Moreover, the acquisition of an osteoblast-like 
phenotype can be demonstrated by histological stains such as 
Alizarin Red and Von Kossa, used to visualize calcium 
deposits in the extracellular matrix [12, 17]. 
 After culture with adipogenic induction medium, WJ-
MSC develop lipid vacuoles (which can be demonstrated by 
Oil Red O staining) and express proteins such as adipo-
nectin, leptin and PPAR-•, confirming the acquisition of a 
differentiated phenotype [12, 18]. 
 WJ-MSC can also differentiate into chondrocyte-like 
cells, which express specific proteins such as collagen type 
II, cartilage oligomeric matrix protein (COMP), and 
aggrecan [19]. Specific histological staining such as Alcian 
blue or Safranin O-Fast Green highlight the deposition of 
mucopolysaccharides and proteoglycans by differentiated 
cells [20]. 
 Indeed, recent data have shown that the differentiative 
ability of WJ-MSC goes far beyond the classic connective 
tissue cell types [21]. Alaminos et al., demonstrated endo-
thelial differentiation of WJ-MSC which expressed typical 
markers of the endothelial lineage [22-24]. Mitchell et al., 
highlighted WJ-MSC capacity to differentiate towards glial 
cells and neurons: induced cells expressed higher levels of 
neuronal markers such as NSE and GFAP than did 
undifferentiated cells [25]. Conconi and colleagues showed 
the myogenic differentiative potential of WJ-MSC cultured 
in a myogenic medium [26]. Wu et al., showed WJ-MSC to 
have myocardiocyte differentiation ability: induced cells 
expressed cardiac myosin and cardiac troponinT (cTnT) 
[27]. These same researchers showed that stem cells injected 
into the viable myocardium bordering an experimental 
infarcted area were incorporated into the vasculature and 
occasionally were positive for cTnT [27]. 
 Apart from differentiation, another key property of MSC 
is the ability to reduce allogeneic lymphocyte proliferation in 
vitro and in vivo, with important consequences for the 
management of acute rejection of infused cells. Recently, 
several studies have shown that MSC express different 
molecules involved in the inhibition of T-cell proliferation 
and dendritic cell differentiation, and other molecules 
responsible for the induction of T-cell anergy and regulatory 
T-cell expansion. Thus it has been hypothesized that MSC 
may have a role in inducing tolerance in the host immune 
system. 
 In particular, we and others highlighted the expression of 
immunomodulatory molecules such as HLA-G, HLA-E, 
PGE2 and HGF in WJ-MSC [12, 28, 29]. The non-classical 
type I HLA molecules are involved in the induction of 
tolerance of NK-cells towards self cells. [30]. It has been 
reported that HLA-G expands CD4+CD25+ FOXP3+ regu-
latory T cells [31]. Moreover, contrary to human BM-MSC, 
WJ-MSC may show a different combination of expression of 
B7-costimulatory factors (CD80+, CD86-). Numerous reports 
suggest that the expression of CD80 in the absence of CD86 
could play a role in the induction of peripheral tolerance, 
perhaps synergistically with HLA-G [32, 33]. 
 Such properties of WJ-MSC could further contribute to 
their therapeutic effect in autoimmune rheumatic diseases 
[34]. 
3. FEATURES AND FUNCTIONS OF CARTILAGE 
 Cartilage is an avascular tissue which is found in 
different parts of the body: on articular surfaces, and in the 
tracheobronchial tree, larynx, ribs, eyelids, ear and nasal 
skeleton [35]. 
 In the fetus, most of the skeleton is composed of 
temporary cartilage that will eventually be replaced by bone. 
Permanent cartilage remains unossified during adult life. 
Cartilage is a semi-transparent, elastic but tough connective 
tissue composed of cells called chondro-cytes surrounded by 
a matrix consisting of glycoproteins known as chondroitin. 
According to the extracellular matrix features, cartilage can 
be classified into three different types: hyaline cartilage, 
white fibrocartilage, and yellow or elastic fibrocartilage. 
 Hyaline cartilage is semi-transparent and has a tough 
but elastic texture. The inner architecture is very simple; it is 
composed of chondrocytes arranged in groups of two or 
more, of rounded or bluntly angular form. A granular matrix 
is organized in concentric lines around cartilage lacunae, 
cavities occupied by a single chondrocyte which following 
the cellular divisions may generate an isogenic series of two, 
four, or eight cells. Hyaline cartilage is typically found in the 
trachea, larynx, and also at the ends of bones where joints 
are formed. 
 White fibrocartilage is a tougher tissue with a higher 
content of anelastic fibrillar collagen fibers. It is found in the 
74     The Open Tissue Engineering and Regenerative Medicine Journal, 2011, Volume 4 La Iacono et al. 
intervertebral disks, articular disks and meniscus [36]. 
Fibrocartilage acts as a shock absorber, providing sturdiness 
without impeding movement. 
 Elastic fibrocartilage is a more elastic cartilage of the 
hyaline type; its matrix, in fact contains abundant elastic 
fibers. This type of cartilage is present in the external ear, 
epiglottis and in parts of the larynx. Elastic cartilage supports 
and maintains the shape of the structure in which it is found 
[36]. 
3.1. Main Features of Articular Cartilage 
 Articular cartilage is a type of hyaline cartilage with a 
granular matrix, and small chondrocytes and nuclei arranged 
in horizontal rows in the uppermost layer close to the 
surface, while nearer to the bone they are arranged in vertical 
rows. Articular cartilages have a tendency to split in a 
vertical direction; in disease this tendency becomes clearly 
manifest [36]. 
 Articular cartilage load-bearing function results from the 
interaction between chondrocytes and extracellular matrix 
(ECM) [37]. Chondrocytes live with a low contribution of 
oxygen and glucose throughout life, in fact they are glyco-
lytic cells [38]. Studies show that mesenchymal stem cells 
may differentiate towards chondrocyte-like cells in 
conditions of hypoxia [39]. 
 The extracellular matrix is composed of three different 
groups of macromolecules: fibrillar and non-fibrillar 
collagens, proteoglicans and collagenous proteins. type II 
and XI give cartilage strength and ensure most of its 
mechanical properties [40-42]. Collagen type VI is typically 
localized around the chondrocytes, allowing their attachment 
to the extracellular matrix as well as being involved in 
transduction of diverse signals to cells. [37, 43-45]. Collagen 
type IX function is not clear, but it seems that, like collagen 
type II, it maintains the integrity of the extracellular matrix. 
Aggrecan (aggregating proteoglycans) embedded in the 
collagen mesh give to cartilage its stiffness to compression, 
resilience and long-term durability [37, 44, 46]. The extra-
cellular matrix contains also small proteoglycans such as 
decorin, fibromodulin, and biglycan. Tenascin and fibro-
nectin are further molecules which modulate the interactions 
between chondrocytes and the surrounding microenviron-
ment [47]. Cartilage oligomeric matrix protein (COMP) and 
other non collagenous proteins are markers of cartilage 
turnover and degeneration and are upregulated following 
proinflammatory stimuli [48-50]. 
3.2. Injury to Articular Cartilage 
 High-impact long-term physical exercise, with intensive 
and repetitive physical stress, may induce alterations in 
cartilage ECM and therefore in chondrocyte functions, 
causing cartilage degeneration [51-53]. 
 According to the World Health Organization (WHO), 
orthopaedic, rheumatic and musculoskeletal diseases are the 
main causes of disability today in the world. Osteoarthritis 
(OA) and rheumatoid arthritis (RA) are the principal diseases 
of the joints. The term “arthritis” literally means inflamma-
tion of the joint but, whereas in osteoarthritis inflammation is 
primarily the result of the pathogenetic process, in 
rheumatoid arthritis it is the main cause [37]. RA is an 
autoimmune disease in which the immune system attacks 
synovial joints and cartilage. At present the causes of this 
inflammatory disorder are unknown. 
 OA, also known as osteoarthrosis or degenerative joint 
disease, is one of the principal disorders in western countries 
which lead to lifetime disability. It can occur as a result of 
advancing age, obesity, trauma or infection of the joint. 
Osteoarthritis is defined as a disease of the elderly, but in 
recent years it has become widespread among younger 
people due to juvenile obesity. Pain, heat, swelling, stiffness 
and limited mobility are the main signs and symptoms of OA 
[38]. This disease involves articular cartilage, synovial mem-
brane, subchondral bone and periarticular soft tissue [54]. 
Drugs used for osteoarthritis treatment reduce only pain and 
inflammation but fail to repair the articular cartilage. 
 Isolated chondral and osteochondral defects are other 
disorders which involve damage of the cartilage. They 
usually occur in adolescent or younger people without 
causing evident symptoms or joint degeneration [55, 56]. 
4. REPAIR OF CARTILAGE  
 Cartilage injury results from an imbalance between ana-
bolic and catabolic functions of the chondrocytes. Further-
more, chondrocytes, the only cell type present in cartilage, 
are fed by diffusion via the synovial fluid thanks to the 
pumping action generated by compression of the articular 
cartilage. For these reasons, the growth and repair of carti-
lage is slow [35]. Two main procedures exist for replacing 
damaged articular cartilage: stimulation of articular cartilage 
repair and transplantation of connective tissue. 
 The penetration of subchondral bone, osteotomy, joint 
distraction, periosteum or perichondrium grafts, application 
or implant of growth factors or artificial matrices which 
promote cartilage formation and cell transplantation of 
chondrocytes and mesenchymal stem cells are some of the 
methods used to repair cartilage [57, 58]. 
 Growth factors such as transforming growth factor-β 
(TGF-β), bone morphogenetic proteins (BMP), insulin like 
growth factor (IGF) and hepatocyte growth factor (HGF) 
affect chondrocyte metabolism and chondrogenesis [59]. In 
particular, BMPs are secreted growth factors of the TGF-β 
superfamily that promote ectopic cartilage and bone forma-
tion and regulate directly the expression of chondrocyte 
genes [60]. Normally bone matrix contains growth factors; in 
fact, in ostechondral injures and joint degeneration these 
molecules are released to repair damaged articular cartilage. 
These factors appear to have greater effects in the treatment 
of isolated chondral and osteochondral defects and mild 
degeneration of cartilage in younger people. 
 Regeneration or repair of cartilage using stem cells can 
involve use of synthetic or natural polymer scaffolds. Fibrin 
promotes the formation of cartilage tissue and the attachment 
of a construct to the recipient site [61]. Collagen is another 
element used for scaffolds, in that it is normally the main 
protein of the extracellular matrix of cartilage [62]. Porous 
polylactic acid, polytetrafluoroethylene, polyester are synthe-
tic polymers applied to restore an articular surface. 
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5. THE USE OF PERINATAL STEM CELL TRANS-
PLANTATION FOR CARTILAGE REPAIR 
 Embryonic stem cells (ESC) are totipotent cells since 
they can generate all cellular types. They derive from 
embryo at the blastula stage. Their use involves embryo 
sacrifice within 14 days following fertilization, therefore 
generating ethical issues. ESC can be indefinitely propagated 
but their graft can cause teratoma formation. For these 
reasons, many researchers used adult stem cells. 
 Adult stem cells maintain normal turnover of organs, can 
differentiate into different cellular types, and can be isolated 
from adults or children without ethical issues.  
 Adult bone marrow mesenchymal stem cells (BM-MSC) 
have been amply investigated for regenerative medicine 
applications. They have fibroblast-like morphology, grow on 
plastic, differentiate into connective cellular types such as 
chondrocytes, osteoblasts and adipocytes, and exhibit im-
munosuppressive ability. While bone marrow represents the 
main source of mesenchymal cells used in clinical settings, 
the number of cells obtained is low [63] and decreases with 
donor age [64]. Therefore, different research groups have 
investigated perinatal stem cells, extracted from alternative 
sources such as human and animal extraembryonic tissues: 
placenta, amniotic membrane, umbilical cord blood, 
Wharton’s jelly or umbilical cord stroma [65, 66]. The 
results of chrondrogenic differentiation experiments with 
these stem cells types are discussed in the following sections 
of the manuscript and schematized in Table 1. 
5.1. Umbilical Cord Blood Mesenchymal Stem Cells 
 Human umbilical cord blood (UCB) has emerged as a 
promising source of mesenchymal stem cells. UCB-MSC 
can readily differentiate into chondrocytes when cultured in 
a chondrogenic medium. Rebelatto and co-workers, in a 
comparative study designed to evaluate the chondrogenic 
differentiative potential of BM-MSC, UCB-MSC and adi-
pose tissue mesenchymal stem cells (ADSC), demonstrated 
that UCB-MSC cultured for 21 days in three different chon-
drogenic media showed a morphology similar to chondro-
cytes, produced mucopolysaccharide, an indicator of chon-
drocyte differentiation, and expressed higher levels of type II 
collagen mRNA than non-induced MSC [67]. 
 Subsequent studies investigated the chondrogenic poten-
tial of human UCB-MSC seeded in scaffolds composed of 
thermoreversible gelation polymer (TGP). UCB-MSC were 
embedded in the TGP in a chondrogenic differentiation 
medium supplemented with TGF-β3 and ascorbic acid. After 
1 week of induction, the UCB-MSC changed their fibroblast-
like morphology to that of a spheroidal one and the size of 
the spheroid increased probably due to the abundant GAG 
accumulation in the extracellular matrix. Moreover, gene 
expression of type II collagen and aggrecan was more 
evident at week 3 and week 2 of induction, respectively, 
whereas SOX 9 gene was expressed stably during the entire 
4 weeks of the induction phase. This study demonstrated that 
chemically synthesized TGP is a suitable three-dimensional 
system for differentiating UBC-MSC towards chondrocytes 
according to their characteristic morphology, GAG accumu-
lation and gene expression [68]. 
 Collagen is certainly the main component of the ECM. 
For this reason different researchers have used it as a carrier 
of MSC in three-dimensional systems. The terminal 10-20 
amino acid residues of collagen do not participate in the 
helical structure formation, and the telopeptide regions are 
the primary cause of immunogenicity [69, 70]. Atelocollagen 
lacks in these regions and therefore is considered a better 
carrier for chondrogenic culture systems. Choi and co-
workers demonstrated a chondrogenic potential of human 
umbilical cord blood-derived multilineage progenitor cells 
(UCB-MLPC) in atelocollagen. The cells were embedded in 
an atelocollagen gel and cultured in chondrogenic induction 
medium, supplemented with TGF-β3, for 3 weeks. The pre-
sence of type II collagen, assessed by immunofluorescence, 
and the expression of aggrecan, Sox-9, TGF-βRI and type II 
collagen mRNA verified by RT-PCR confirmed the chon-
drogenic potential. Thanks to the atelocollagen gel culture 
system, the induced cells maintained a round morphology 
and expressed cartilage specific molecule such as type II 
collagen and GAG. Moreover, the stiffness of post-cultured 
atelo-collagen gel was higher than that of pre-cultured atelo-
collagen gel [71]. 
 In recent years, animal models of chondrogenic different-
tiation of UCB-MSC have also been explored. Preliminary 
studies carried out by Seo and colleagues highlighted the 
chondrogenic potential of canine UCB-MSC. The pellet 
obtained after 2-3 weeks of culture with a chondrogenic me-
dium supplemented with BMP-2, appeared white in colour 
and formed aggregates in the bottom of the tube. Moreover, 
canine UCB-MSC showed positivity for Toluidine blue, a 
specific dye for the highly sulphated proteoglycans of 
cartilage matrices [72]. 
 Reed et al., demonstrated the ability of horse UCB-MSC 
to differentiate into mesodermal cellular lineages. In parti-
cular, foal UCB-MSC were cultured in a chondrogenic 
medium supplemented with ascorbic acid, dexamethasone 
and TGF-β1. Alcian blue and Safranin staining revealed the 
presence of mucopolysaccharides and glycosaminoglycans 
respectively, while molecular analysis highlighted expres-
sion of Sox 9 and COL2A1 mRNA. These data demonstrated 
that horse UBC-MSC can differentiate into chondrocyte-like 
cells and therefore could play a role in the treatment of horse 
cartilage diseases [73]. 
5.2. Placenta-Derived Mesenchymal Stem Cells  
 Although umbilical cord blood is a valid source of MSC, 
the frequency of these cells is low and the isolation method 
poses some problems. Therefore, studies have been carried 
out on MSC derived from placenta. Zhang and co-workers 
isolated mesenchymal cells from chorionic villi in the human 
placenta (hPDMSC) and evaluated their ability to different-
tiate into chondrocyte-like cells both in vitro and in vivo. 
hPDMSC were cultured for 21 days in a chondrogenic 
medium consisting of dexametasone, BMP-2 and TGF- β3. 
After a 3-week induction phase, the cellular pellet obtained 
was white and opaque, and after 1 week the cells had already 
changed their morphology. Toluidine blue staining revealed 
a metachromatic matrix, immunohistochemistry showed 
presence of type II collagen and RT-PCR highlighted the 
expression of COL2A1, COL10A1, BMP-2, BMP-2R and 
aggrecan [74]. In the presence of a three-dimensional 
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scaffold composed of atelocollagen, hPDMSC differentiated 
towards chondrocytes, and toluidine blue staining and RT-
PCR confirmed the results of the pellet culture. After trans-
plantation of the pre-induction hPDMSC-loaded collagen 
sponge into nude mice-generated cartilage or transplantation 
of hPDMSC in collagen sponge into articular osteochondral 
defects in nude rats, hypertrophic repair cartilage was 
formed. Toluidine blue staining was performed in both in 
vivo experiments [74]. 
 Amniotic membrane is composed of two cellular types: 
human amniotic epithelial cells (hAEC) derived from 
embryonic ectoderm and human amniotic mesenchymal 
stromal cells derived from embryonic mesoderm (hAMSC). 
hAMSC are similar to BM-MSC: they show a fibroblastic-
like morphology and can differentiate towards different 
mesodermal cellular lineages. Prado and colleagues, in a 
comparative study on the multilineage differentiation poten-
tial of both human amniotic cells, observed that hAMSC cul-
tured in a medium supplemented with chondrogenic factors 
differentiated towards chondrocyte-like cells. The acquisi-
tion of chondrocyte phenotype was confirmed by toluidine 
blue staining and expression of Col II, aggrecan and Sox 9 -
by qRT-PCR and immunohystochemical analyses. In sum-
mary, this study showed hAMSC to have a better chondro-
genic differentiation potential than hAEC [75]. 
5.3. Mesenchymal Stem Cells Derived from Amniotic 
Fluid  
 Recently multipotent stem cells have also been isolated 
from animal and human amniotic fluid (AF). AF-derived 
mesenchymal stem cells (AF-MSC) have a higher proli-
ferative capacity, maintain their pluripotency for longer and 
differentiate towards several mesodermal cellular types. It 
has been hypothesized that these cells are in an intermediate 
developmental stage between embryonic stem cells and 
lineage-restricted adult stem cells [76]. 
 Kolambkar and coworkers investigated the chondrogenic 
potential of AF-MSC in pellet and alginate hydrogel culture. 
After 3 weeks in pellet culture, the amount of GAG was 
higher if these cells were cultured in a medium supple-
mented with TGF-β1 compared to with TGF-β3 or TGF-β3 + 
BMP-2. Histological staining confirmed the presence of 
GAG indicating the formation of a cartilaginous matrix. The 
chondrogenic potential of AF-MSC was demonstrated also 
in alginate gels in the presence of TGF-β1, after 3 weeks. 
The differentiated cells expressed type II collagen, the main 
molecule of the cartilage ECM [77]. 
 Kunisaki and colleagues observed cartilage formation 
from mesenchymal stem cells derived from ovine amniotic 
fluid. These cells were cultured as micromass pellet in a 
chondrogenic medium containing IGF-1 and TGF-β2 for 6-
12 weeks. Moreover, they were seeded into biodegradable 
polyglycolic acid scaffolds cultured in chondrogenic medium 
within a rotating bioreactor for 10-15 weeks. Both in the 
micromass pellets and 3D engineered constructs, AF-MSC 
were capable of chondrogenic differentiation and showed 
lower collagen type II levels and higher elastin levels than 
native fetal hyaline cartilage. In summary, ovine AF-MSC 
differentiated towards cells with a histological pattern 
similar to that of fetal hyaline cartilage. Therefore they could 
be used for hyaline-type grafts [78]. 
 The same researchers performed a comparative analysis 
of three-dimensional cartilagineous constructs engineered 
from different ovine perinatal mesenchymal sources such as 
amniotic fluid, neonatal bone marrow and umbilical cord 
blood. In particular, these cells were seeded in synthetic 
polyglycolic acid scaffolds and maintained in chondrogenic 
medium supplemented with TGF-β2. After 12-15 weeks all 
constructs were compared to hyaline and elastic cartilage by 
gross inspection, histological staining and quantitative extra-
cellular matrix assays. Findings showed that mesenchymal 
cells had lower levels of GAGs than native hyaline cartilage, 
and in particular AF derived constructs showed higher 
elastin levels than the other two constructs, being thus 
perfectly comparable to native elastic cartilage [79]. 
5.4. Mesenchymal Stem Cells Derived from Human 
Umbilical Cord Stroma and Wharton’s Jelly 
 Umbilical cord (UC) is a non-controversial and non-
invasive source of mesenchymal stem cells. In recent years, 
also these cells have been investigated for their dif-
ferentiation ability towards chondrocytes.  
 Arufe and coworkers demonstrated that UC-MSC are 
able to differentiate into chondrocyte-like cells if cultured in 
a medium supplemented with ascorbic acid , transferrin, 
dexamethasone, retinoic acid and TGF-β3 for up to 46 days. 
The acquisition of a chondrocyte phenotype was evaluated 
by expression of COL1, COL2 and COL10 at different days 
of culture by qRT-PCR and immunohistochemistry analysis. 
Moreover, a secretome study evaluated the expression of 
proteins such as decorin, galectin-1 and chitinase, typical of 
native cartilage ECM. The results highlighted chondrogenic 
ability of UC stroma-derived MSC and therefore their 
possible use for cell therapy in articular diseases [80]. 
 Wang and colleagues demonstrated that seeding density 
of cells derived from Wharton’s jelly (WJ-MSC) in poly-
glycolic acid scaffolds (PGA), in the presence of chondro-
genic medium, had important effects on their chondrogenic 
potential. WJ-MSC at different density (5, 25, and 50 million 
cells/ml) were cultured in a chondrogenic medium within 
PGA scaffolds for 4 weeks. Biochemical and immunohisto-
chemical analyses showed more GAGs and collagen type I 
and II contents in higher density groups (25 and 50 million 
cells/ml) than in a lower density group (5 million cells/ml). 
Mechanical integrity was also maintained more in the higher 
density than lower density group. In conclusion, this study 
underlined the potential for chondrogenic differentiation by 
WJ-MSC in a three-dimensional system and the importance 
of higher seeding density to promote biosynthesis and mech-
anical integrity for a possible application in fibrocartilage 
tissue engineering [81]. 
 More recently a comparative study between human BM-
MSC and human WJ-MSC for cartilage tissue engineering 
was performed. Both cell types were seeded on PGA 
scaffolds at 25 million cells/ml and cultured in chondrogenic 
differentiation medium for 6 weeks. WJ-MSC produced 
more GAGs than BM-MSC at both 3 and 6 weeks. 
Moreover, COL1 production was higher in WJ-MSC at 6  
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Table 1.  Summary of Literature Reports Indicating the Differentiative Ability of Perinatal MSC Populations Towards 
Chondrocyte-Like Cells 
 
MSC population Chondrocyte differentiation protocol Analysis of marker expression 
Functional features and 
positivity to histological stains Ref. 
Human Bone marrow 
mesenchymal stem cells 
HumanAdipose tissue 
derived mesenchymal stem 
cells 
Human Umbilical cord blood 
derived mesenchymal stem 
cells(UCB-MSC) 
Three steps, 21 days protocol: 
I step: DMEM-HG with 15% FCS, 
dexamethasone, ascorbic acid 2-phosphate, 
sodium pyruvate, TGF-β1, insulin-transferrin-
selenium-X(ITS-X) 
II step: DMEM-HG with 1%FCS, TGF-β1, 
insulin, AA 
III step: differentiation Basal Medium 
Chondrocyte with hMSC chondrogenic 
SingleQuots 
I. type II collagen by RT-
PCR and q-PCR 
Paraffin sections stained with HE, 
Mallory or Toluidine Blue 
[67] 
Human Umbilical cord blood 
derived mesenchymal stem 
cells (UCB-MSC) 
One step, three weeks protocol: 
UCB-MSC in the TGP cultured in DMEM with 
AA, TGF-β3, sodium pyruvate, ITS+ Premix 
I. type II collagen , 
aggrecan and SOX9 by 
RT-PCR 
I. GAG accumulation by ELISA 
II. DNA assay by Hoechst 33258 
fluorimetric detection method 
[68] 
Human Umbilical cord blood 
derived multilineage 
progenitor cells (MLPC) 
One step, three weeks protocol: 
MLPC in atelocollagen for 3 weeks 
In hMSC Chondrogenic BulletKit with TGF-β3 
I. type II collagen by IF 
II. type II collagen, Sox 9, 
aggrecan and TGF-βR1 by 
RT-PCR 
 [71] 
Canine umbilical cord blood 
derived mesenchymal stem 
cells 
One step- 3 weeks protocol: 
DMEM with 10% FCS with BMP-2 
None Toluidine Blue staining for GAGs [72] 
Equine umbilical cord blood 
mesenchymal stem cells 
One step, 21 daysprotocol: 
DMEM with ITS-X; TGF-β1 
Sox 9 and collagen 2AI by 
RT-PCR after 7 and 21 
days  
I. Alcian Blue stain for presence of 
mucopolysaccharides 
II. Safranin staining for GAGs 
[73] 
Human Mesenchymal 
progenitor cells derived from 
chorionic villi (hPDMC) 
Pellet culture: DMEM-HG with TGF-β3, dex, 
BMP-2, ascorbate-2-phosphate,praline, pyruvate, 
ITS+Premix for 21 days 
Culture in atelocollagen gel: DMEM-HG with 
TGF-β3, dexamethasone, BMP-2, ascorbate-2-
phosphate,praline pyruvate, ITS+Premix for 3 
weeks 
Pellet culture: 
I type II collagen by IHC 
II. Sox 9, COL2A1, 
aggrecan, COL10A1, 
BMP-2, BMP-6 by RT -
PCR  
Culture in atelocollagen 
gel: 
Sox 9, COL2A1, 
aggrecan, COL10A1, 
BMP-2, BMP-6 by RT -
PCR 
In vitro: toluidine blue staining for 
GAGs in pellet culture and culture 
in atelocollagen 
In vivo: subcutaneous 
transplantation of hPDMC in 
atelocollagen sponge into nude 
mice. 
Toluidine Blue for metachromic 
matrix 
In vivo: transplantation of hPDMC 
in collagen sponge into articular 
osteochondral defect in nude rats. 
Toluidine blue staining 
Expression of β-2 microglobulin 
by FITC 
[74] 
Human amniotic epithelial 
cells 
Human amniotic membrane 
derived mesenchymal stem 
cells 
Two steps, 23 days protocol: 
DMEM with 15% FBS, AA, MTG for 2 days. 
DMEM with 15% knockout serum replacement, 
AA, Dex, transferrin, RA and TGF-β3 for 21 
days. 
I.Collagen I, collagen II, 
aggrecan by IHC 
II. Collagen II, Sox 9, 
aggrecan by qRT-PCR 
Toluidine blue staining for 
proteoglycans  
[75] 
Human Amniotic fluid 
derived mesenchymal stem 
cells  
Cell culture: one step protocol, for 3 weeks: 
 DMEM-HG with ITS+Premix, penicillin, 
streptomycin, L-glutamine, dexamethasone, L-
proline, ascorbic-2-phosphate and TGF-β1, TGF-
β3, BMP-2, IGF-1  
Alginate gel:  one step protocol for 3 weeks: 
DMEM-HG with penicillin, streptomycin, L-
glutamine; after solidification in basal medium 
with TGF-β1 
Cell culture: 
Type II collagen by IHC 
 
 
Alginate gel: 
Type II collagen by IF 
Cell culture 
DNA assay by Hoescht 33258 dye 
GAG assay by dimethyl-methylene 
blue 
Alginate gel: None 
[77] 
Ovine amniotic fluid derived 
mesenchymal progenitor 
cells 
Micromass pellet: one step protocol, 6-12 weeks 
DMEM-HG with dexamethasone, ascorbic acid 
2-phosphate, penicillin G sodium, streptomycin 
sulphate, sodium pyruvate, L-proline, TGF-β2, 
IGF-1, ITS-plus 
Micromass pellet 
I. Aggrecan by IHC 
 
Micromass pellet 
I. toluidine blue staining for GAGs 
II. H&E staining 
 
[78] 
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(Table 1) Contd…. 
MSC population Chondrocyte differentiation protocol Analysis of marker expression 
Functional features and 
positivity to histological stains Ref. 
 3D engineered constructs: one step protocol, 10-
15 weeks: 
DMEM-HG with dexamethasone, ascorbic acid 
2-phosphate, penicillin G sodium, streptomycin 
sulphate, sodium pyruvate, L-proline, TGF-β2, 
IGF-1, ITS-plus 
3D engineered constructs 
I. proteoglycans and 
aggrecan by IHC 
3D engineered constructs 
I. toluidine blue staining for GAGs 
II. quantitative GAGs assay 
III. quantitative DNA assay 
IV. quantitative collagen type II 
assay 
 
Ovine  amionitic fluid 
mesenchymal progenitor 
cells (MPC) 
Ovine  neonatal bone 
marrow MPC 
Ovine umbilical cord blood 
MPC 
One step, 12 weeks protocol: 
Cells seeded in polyglycol acid in  
DMEM with dexamethasone, ascorbic acid 2-
phosphate, penicillin G sodium, streptomycin 
sulphate, sodium pyruvate, L-proline, TGF-β1, 
IGF-1, ITS+ 
Aggrecan and cartilage 
link protein by IHC 
Toluidine blue staining for GAG 
Von Gieson staining for elastin 
q-GAG assay 
q-DNA assay 
q-α-elastin 
[79] 
Human umbilical cord 
stroma derived mesenchymal 
stem cells 
One step protocol, for 4-7-14-28-46 days: 
 
DMEM with 15% knockout serum replacement, 
AA, transferrin, dexamethasone, RA, TGF-β3 
I. COL1, COL2, COL10 
by IHC  
II. COL1, COL2, COL10 
by qRT-PCR 
I. H&E to evaluate distribuition of 
matrix 
II. Safranin O staining for 
proteoglycans 
III. Alizarin blue staining for 
polysaccharides 
IV. densitometric analysis of 
COL1, COL2, COL10 
V. secretome analysis during 
chondrogenesis of 342 proteins  
[80] 
Wharton’s Jelly derived 
mesenchymal stem cells 
(WJ-MSC) 
One step, 4 weeks protocol: 
WJ-MSC seeded in PGA scaffolds 
DMEM-HG with non essential amino acid, 
ascorbic acid 2-phosphate, dexamethasone, 
sodium pyruvate, L-proline, TGF-β1 
COL1, COL2, aggrecan 
by IHC 
I. GAGs assay 
II. hydroxyproline assay 
III. Mechanical tests 
[81] 
Bone marrow derived 
mesenchymal stem cells 
Wharton’s Jelly derived 
mesenchymal stem cells  
One step- WJ-MSC into PGA scaffodls for 6 
weeks 
DMEM-HG with non essential amino acid, 
ascorbic acid 2-phosphate, dexamethasone, 
sodium pyruvate, L-proline, TGF-β1 
I. COL1,COL2, aggrecan 
by IHC 
II. COL1,COL2, aggrecan 
by RT-PCR 
I.Hematoxylin staining 
II. DNA content  assay 
III. GAGs content assay 
IV. hydroxyproline content assay 
[82] 
Wharton’s Jelly derived 
mesenchymal stem cells 
WJ-MSC into PLLA scaffold for 3 weeks 
DMEM-HG with non essential amino acid, 
ascorbic acid 2-phosphate, dexamethasone, 
sodium pyruvate, L-proline, TGF-β1 
Osteochondral composites:for 3 weeks  
DMEM-LG with FBS, ascorbic acid 2-phosphate, 
dexamethasone, L-proline, IGF-1 
I. COL1, COL2, aggrecan 
by IHC 
II. COL1,COL2, aggrecan 
by RT-PCR 
I. DNA content  assay 
II. GAGs content assay 
III. hydroxyproline content assay 
IV. calcium deposition assay 
V. Safranin O staining 
[84] 
Equine umbilical cord matrix 
cells 
One step, 21 days protocol: 
Serum-free DMEM-LG with ITS + premix TGF-
β1 
None I. toluidine blue staining  [85] 
Abbreviations: DMEM: Dulbecco’s Modified Eagle’s Medium; HG: high glucose, LG: low glucose, FCS: fetal calf serum; FBS: fetal bovine serum, TGF-β: transforming growth 
factor- β, AA: ascorbic acid; ITS: insulin-transferrin-selenite; HE: haematoxylin-eosin; GAGs: glycosaminoglycans; ITS+Premix: insulin, transferring, selenius acid, bovine serum 
albumin, linoleic acid; RA: retinoic acid; MTG: monothioglycerol; IGF: insulin growth factor; COLI: collagen I, COL II: collagen II, Col10: collagen 10, BMP-2: bone 
morphogenetic protein-2. 
 
weeks. Based on the ECM-molecules expression profile of 
WJ-MSC, consisting of a large amount of type I collagen, 
lower content of type II collagen and moderate amounts of 
aggrecan, these cells could be considered candidates for 
fibrocartilage tissue engineering such as for the temporo-
mandibular joint disc or the knee meniscus [82]. 
 In a very recent report, Fong and co-workers showed that 
human WJ-MSC undergo enhanced chondrogenic differen-
tiation when cultured on nanofibrous substrates with a 
sequential two cultures medium environment. The resear-
chers highlighted that in particular WJ-MSC were able to 
upregulate the production of hyaluronic acid and GAGs, as 
well as the expression of key genes as SOX9, COMP, 
Collagen type II and FMOD [83]. 
 Osteochondral tissue is composed of cartilage and bone: 
in osteochondral defects both tissues necessitate regenera-
tion. WJ-MSC are considered excellent candidates for osteo-
chondral tissue engineering. Wang and co-workers deve-
loped a supportive structure which mimics native osteochon-
dral tissue. Two groups of WJ-MSC were seeded in different 
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poly-L-lactic-acid (PLLA) scaffolds with chondrogenic and 
osteogenic medium respectively for 3 weeks. After this 
period of culture, chondrogenic and osteogenic constructs 
were sutured together surgically to create four different 
osteochondral assemblies: one with two chondrogenic cons-
tructs, one with two osteogenic constructs, one with a 
chondrogenic and an osteogenic construct and the last with a 
chondrogenic and an osteogenic construct with a layer of 
undifferentiated WJ-MSC. Histological staining and 
immunohistochemical analysis confirmed the presence of 
GAG, type I collagen and calcium at the interface between 
chondrogenic and osteogenic sections when a layer of 
undifferentiated cells was present with respect to the other 
three investigated composites [84]. 
 Hoynowski and coworkers showed the chondrogenic 
differentiation potential of WJ-MSC derived from horse. 
These cells, cultured in a chondrogenic medium, changed 
their morphology from fibroblastoid to spheroid. Toluidine 
blue staining highlighted the presence of aggregates trans-
formed into spherical masses after chondrogenic induction. 
This study demonstrated that equine WJ-MSC can prolife-
rate extensively, differentiate into several cellular types and 
therefore could play a role in stem cell-based therapies in the 
horse [85]. 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 Cartilage tissue engineering using multipotent stem cells 
is an evolving field in regenerative medicine. The low in 
vivo self-repair of cartilage and the occurrence of a number 
of dysfunctions in cartilagineous tissues, of both post-trau-
matic and autoimmune origin, render more compelling the 
need for successful cellular therapy approaches. In this 
perspective, perinatal stem cells, derived from fetus-
associated structures at birth, share a number of positive 
features which enable their use for these tissue engineering 
applications. In particular, Wharton’s jelly-derived cells are 
being viewed as a very promising cellular source due to both 
their differentiative and immunomodulatory properties. WJ-
MSC have been demonstrated to successfully differentiate 
into cells resembling mature chondrocytes. Moreover, their 
peculiar features of low immunogenicity and their potential 
to induce immune tolerance in the host further justify the 
efforts for their use in osteoarthritis, rheumatoid arthritis and 
other disease settings. Further research is needed to standard-
ize the differentiation protocols used as well as the scaffold 
composition. However, the in vitro and in vivo results 
obtained so far are encouraging and indicate that one of the 
foremost uses of WJ-MSC could be in tissue engineering of 
cartilagineous tissues. 
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